Kedudukan dalam Saham
#28218
Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based... Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tolerance platform capable of selectively suppressing specific immune responses. This Veto Cell technology finds application in numerous areas, including enhancing the acceptance of stem cell transplants for conditions like lymphoma, leukemia, and multiple myeloma. Furthermore, it is utilized in treating end-stage kidney disease, various other non-malignant organ diseases, and a spectrum of both cancerous and non-malignant illnesses. Founded in 2012, Cell Source, Inc. maintains its corporate headquarters in New York, New York.
Harga Saham
$0.4
Disegerakkan terakhir: 2026-10-02
Perubahan (1 hari)
-14.88%
Perubahan (1 tahun)
8.11%
Perdagangan Cell Source, Inc. (CLCS)
Harga CLCS dengan permodalan pasaran b
Modal pasaran bagi Cell Source, Inc.(CLCS)
Modal Pasaran: $27.18M
Sehingga October 2026, Cell Source, Inc. mempunyai modal pasaran sebanyak $27.18M. Ini menjadikan Cell Source, Inc. syarikat ke-28218th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Cell Source, Inc. dari 2014 hingga 2026
CLCS berbanding dengan 5 teratas yang paling popular stocks
| Harga CLCS |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.807T
|
+21,367,012.68%
|
|
|
|
|
$4.891T
|
+17,994,900.12%
|
|
|
|
|
$4.177T
|
+15,369,855.18%
|
|
|
|
|
$3.919T
|
+14,417,670.59%
|
|
|
|
|
$2.724T
|
+10,022,661.63%
|
